Fidelity Investments
APRE icon

Fidelity Investments’s Aprea Therapeutics APRE Stock Holding History

Fidelity Investments’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-45
Closed -$36 – 5790
2026
Q2 		$36 Buy
+45
New +$38 ﹤0.01% 5464
2025
Q3 		– Sell
-501
Closed -$852 – 5374
2025
Q2 		$852 Buy
+501
New +$854 ﹤0.01% 4980
2024
Q2 		– Sell
-161
Closed -$1.08K – 5355
2024
Q1 		$1.08K Buy
+161
New +$1K ﹤0.01% 4774
2022
Q1 		– Sell
-10
Closed -$1K – 5440
2021
Q4 		$1K Buy
+10
New +$883 ﹤0.01% 4086
2021
Q1 		– Sell
-63,064
Closed -$6.21M – 3952
2020
Q4 		$6.21M Sell
63,064
-94,933
-60% -$45.1M ﹤0.01% 2121
2020
Q3 		$76M Buy
157,997
+87
+0.1% +$48.7K 0.01% 1046
2020
Q2 		$122M Buy
157,910
+6,587
+4% +$4.32M 0.01% 803
2020
Q1 		$105M Buy
151,323
+44,202
+41% +$32.4M 0.01% 735
2019
Q4 		$98.3M Buy
+107,121
New +$59M 0.01% 917

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Fidelity Investments's APRE Position: Q3 2026 in Review

Fidelity Investments sold out of Aprea Therapeutics (APRE) in Q3 2026, closing a stake of 45 shares — an estimated $36 sold.

Fidelity Investments first reported a position in APRE in Q4 2019 and held it in 9 quarters. The position peaked at $122M in Q2 2020. 19 funds tracked by Wall St. Rank hold APRE as of Q3 2026.

  • Fidelity Investments reported no remaining Aprea Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Fidelity Investments sold 45 Aprea Therapeutics shares in Q3 2026, an estimated $36.
  • Fidelity Investments first reported a position in Aprea Therapeutics in Q4 2019 and held it in 9 quarters.
  • Fidelity Investments's Aprea Therapeutics position peaked at $122M in Q2 2020.
  • 19 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.